GREENVILLE, S.C., Nov. 30 /PRNewswire-FirstCall/ -- Budimir Drakulic, Chief Technology Officer and inventor of Signalife’s revolutionary ECG technology has been working with the world famous Cleveland Clinic physicians and Champ Car Medical Director Dr. Chris Pinderski for more than a year. The study utilizes Signalife’s ECG technology in a Hi-Tech Heart Monitor. The device, which is a vest, is worn under the driver’s suit while racing of speeds greater than 200 miles per hour.

Signalife’s superior technology was chosen for the study due to the clarity of the signal in harsh environments. The heart monitor has shown clinical value to physicians in determining what is going on with the Champ Car drivers during testing and races. Pam Bunes, President and CEO of Signalife states, “We were thrilled to have been selected for this study and look forward to future opportunities to apply our technology in the ambulatory heart monitoring industry.” Download PDF

About Heart Tronics, Inc.
Heart Tronics, Inc. engages in the research, development, and marketing of signal-monitoring devices for detecting diseases. It primarily offers patient modules that are used as part of a heart monitor system to acquire, amplify, and process physiological signals associated with a patient’s cardiovascular system. Heart Tronics is based in Greenville, South Carolina. For more information visit http://www.Heart Tronics.com.

Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are “forward-looking” statements. Forward-looking statements involve known and unknown risks, which may cause Heart Tronics’s actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Heart Tronics’s technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Heart Tronics’s technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Heart Tronics’s technology, and the unavailability of financing to complete management’s plans and objectives, including the development of heart monitoring and other biomedical incorporating Heart Tronics’s technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Heart Tronics’s filings with the Securities and Exchange Commission.